DK2060266T3 - Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb - Google Patents

Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb

Info

Publication number: DK2060266T3
Authority: DK; Denmark
Prior art keywords: receptor agonist; therapeutic interventions; selective receptor; selective; receptors
Prior art date: 2004-03-17

Application number

DK09075024.1T

Other languages

English (en)

Inventor

Thue Schwartz

Original Assignee

7Tm Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-17

Filing date

2005-03-17

Publication date

2011-11-14

2005-02-14 Priority claimed from GB0503110A external-priority patent/GB0503110D0/en

2005-03-17 Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As

2011-11-14 Application granted granted Critical

2011-11-14 Publication of DK2060266T3 publication Critical patent/DK2060266T3/da

Links

239000000018 receptor agonist Substances 0.000 title abstract 3
229940044601 receptor agonist Drugs 0.000 title abstract 3
230000001225 therapeutic effect Effects 0.000 title 1
102000028435 Neuropeptide Y4 receptor Human genes 0.000 abstract 2
108010002245 Neuropeptide Y4 receptor Proteins 0.000 abstract 2
102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 abstract 1
101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 abstract 1
102000018886 Pancreatic Polypeptide Human genes 0.000 abstract 1
108700020479 Pancreatic hormone Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)

DK09075024.1T 2004-03-17 2005-03-17 Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb DK2060266T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200400436		2004-03-17
US55893204P	2004-04-01	2004-04-01
US58596404P	2004-07-06	2004-07-06
GB0503110A GB0503110D0 (da)	2005-02-14	2005-02-14
EP05716258A EP1729792B1 (en)	2004-03-17	2005-03-17	Y4 selective receptor agonist for therapeutic interventions

Publications (1)

Publication Number	Publication Date
DK2060266T3 true DK2060266T3 (da)	2011-11-14

Family

ID=43302286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09075024.1T DK2060266T3 (da)	2004-03-17	2005-03-17	Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb

Country Status (15)

Country	Link
US (1)	US20080269114A1 (da)
EP (3)	EP2057996A3 (da)
JP (1)	JP2007529463A (da)
AT (2)	ATE519495T1 (da)
AU (1)	AU2005224028B2 (da)
BR (1)	BRPI0508935A (da)
CA (1)	CA2560174A1 (da)
DE (1)	DE602005025199D1 (da)
DK (1)	DK2060266T3 (da)
EA (1)	EA012071B1 (da)
GB (1)	GB2427551B (da)
IL (1)	IL177681A0 (da)
MX (1)	MXPA06010345A (da)
PL (1)	PL2060266T3 (da)
WO (1)	WO2005089786A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1933848A (zh) *	2004-03-17	2007-03-21	7Tm制药联合股份有限公司	用于治疗性干预的y2选择性受体激动剂
WO2005089790A2 (en) *	2004-03-17	2005-09-29	7Tm Pharma A/S	Y2/y4 selective receptor agonists for therapeutic interventions
WO2006091505A2 (en) *	2005-02-24	2006-08-31	Bayer Pharmaceuticals Corporation	Neuropeptide y receptor agonists
ES2407107T3 (es) *	2005-08-26	2013-06-11	Abbvie Inc.	Análogos de alfa-MSH terapéuticamente activos
CN101268099A (zh) *	2005-09-21	2008-09-17	7Tm制药联合股份有限公司	用于治疗性干预的y4选择性受体激动剂
EP1934245B1 (en) *	2005-09-21	2011-07-13	7TM Pharma A/S	Y2 selective receptor agonists for therapeutic interventions
CA2638943A1 (en) *	2006-02-24	2007-09-07	Banyu Pharmaceutical Co., Ltd.	Npy y4 agonist as therapeutic agent for disease accompanied by intestinal tract dysfunction
EP2152707B1 (en)	2007-05-04	2012-06-20	Bristol-Myers Squibb Company	[6,5]-bicyclic gpr119 g protein-coupled receptor agonists
PE20090222A1 (es)	2007-05-04	2009-03-27	Bristol Myers Squibb Co	Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
BRPI0814629A2 (pt) *	2007-07-09	2015-01-27	Imp Innovations Ltd	Compostos e seus efeitos sobre o comportamento alimentar
PL2170864T3 (pl)	2007-07-17	2012-02-29	Bristol Myers Squibb Co	Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
RU2504550C2 (ru) *	2008-05-16	2014-01-20	Ново Нордиск А/С	Длительно действующие агонисты рецепторов y2 и(или) y4
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment
WO2010102041A2 (en) *	2009-03-04	2010-09-10	Meyer Nutriceuticals, Llc	Composition and method for control of diabetes
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
US8415367B2 (en)	2010-04-08	2013-04-09	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
CN102971311B (zh)	2010-05-06	2015-07-08	百时美施贵宝公司	作为gpr119调节剂的二环杂芳基化合物
EP2566862B1 (en)	2010-05-06	2015-09-16	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
KR102072202B1 (ko)	2012-03-22	2020-01-31	노보 노르디스크 에이/에스	Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
US9174965B2 (en)	2012-05-16	2015-11-03	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
RS58039B1 (sr)	2013-05-02	2019-02-28	Novo Nordisk As	Oralno doziranje glp-1 jedinjenja
WO2015061272A1 (en)	2013-10-22	2015-04-30	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US10583172B2 (en)	2013-11-15	2020-03-10	Novo Nordisk A/S	HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2015071355A1 (en)	2013-11-15	2015-05-21	Novo Nordisk A/S	Selective pyy compounds and uses thereof
MX392572B (es)	2015-06-12	2025-03-24	Novo Nordisk As	Compuestos del péptido yy (pyy) selectivos y sus usos.
CN109715637B (zh)	2016-07-22	2022-04-05	百时美施贵宝公司	葡萄糖激酶激活剂及其使用方法
AR114353A1 (es)	2018-02-02	2020-08-26	Novo Nordisk As	Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
GB202213305D0 (en) *	2022-09-12	2022-10-26	Univ Ulster	Compositions for use in the treatment of diabetes or obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
CA2215694A1 (en)	1995-03-17	1996-09-26	Novo Nordisk A/S	Insulin derivatives
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
JP2006516262A (ja) *	2002-12-17	2006-06-29	ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド	Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
EP1789440A4 (en) *	2004-02-11	2008-03-12	Amylin Pharmaceuticals Inc	REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment

2005
- 2005-03-17 DK DK09075024.1T patent/DK2060266T3/da active
- 2005-03-17 EP EP09075040A patent/EP2057996A3/en not_active Withdrawn
- 2005-03-17 BR BRPI0508935-2A patent/BRPI0508935A/pt not_active IP Right Cessation
- 2005-03-17 JP JP2007503303A patent/JP2007529463A/ja not_active Ceased
- 2005-03-17 AT AT09075024T patent/ATE519495T1/de not_active IP Right Cessation
- 2005-03-17 US US10/592,779 patent/US20080269114A1/en not_active Abandoned
- 2005-03-17 DE DE602005025199T patent/DE602005025199D1/de not_active Expired - Lifetime
- 2005-03-17 MX MXPA06010345A patent/MXPA06010345A/es not_active Application Discontinuation
- 2005-03-17 EP EP09075024A patent/EP2060266B1/en not_active Expired - Lifetime
- 2005-03-17 WO PCT/EP2005/002983 patent/WO2005089786A2/en not_active Ceased
- 2005-03-17 AT AT05716258T patent/ATE490779T1/de not_active IP Right Cessation
- 2005-03-17 EA EA200601720A patent/EA012071B1/ru unknown
- 2005-03-17 AU AU2005224028A patent/AU2005224028B2/en not_active Ceased
- 2005-03-17 GB GB0618824A patent/GB2427551B/en not_active Expired - Fee Related
- 2005-03-17 CA CA002560174A patent/CA2560174A1/en not_active Abandoned
- 2005-03-17 EP EP05716258A patent/EP1729792B1/en not_active Expired - Lifetime
- 2005-03-17 PL PL09075024T patent/PL2060266T3/pl unknown
2006
- 2006-08-24 IL IL177681A patent/IL177681A0/en unknown

Also Published As

Publication number	Publication date
EA200601720A1 (ru)	2007-04-27
EA012071B1 (ru)	2009-08-28
MXPA06010345A (es)	2007-06-19
WO2005089786A3 (en)	2006-06-15
DE602005025199D1 (en)	2011-01-20
PL2060266T3 (pl)	2012-01-31
ATE490779T1 (de)	2010-12-15
EP2060266A1 (en)	2009-05-20
JP2007529463A (ja)	2007-10-25
GB0618824D0 (en)	2006-11-01
WO2005089786A2 (en)	2005-09-29
AU2005224028A1 (en)	2005-09-29
EP1729792A2 (en)	2006-12-13
ATE519495T1 (de)	2011-08-15
BRPI0508935A (pt)	2007-09-25
AU2005224028B2 (en)	2011-05-26
EP1729792B1 (en)	2010-12-08
US20080269114A1 (en)	2008-10-30
EP2060266B1 (en)	2011-08-10
GB2427551A (en)	2007-01-03
EP2057996A2 (en)	2009-05-13
IL177681A0 (en)	2006-12-31
EP2057996A3 (en)	2009-11-04
CA2560174A1 (en)	2005-09-29
GB2427551B (en)	2007-05-30

Publication	Publication Date	Title
ATE490779T1 (de)	2010-12-15	Y4-selektive rezeptoragonist für therapeutische interventionen
DK1734971T3 (da)	2012-02-13	Indretning på polymerbasis med forsinket frigivelse
CL2008003847A1 (es)	2009-11-27	Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
NO20081908L (no)	2008-06-20	Selektive Y4-reseptoragonister for terapeutiske intervensjoner
DE602005015577D1 (de)	2009-09-03	Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE451364T1 (de)	2009-12-15	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE490239T1 (de)	2010-12-15	Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren
NO20081910L (no)	2008-06-20	Selektive Y2-reseptoragonister for terapeutiske intervensjoner
DK2119715T3 (da)	2012-09-10	Benzimidazolderivat og dets anvendelse som AII-receptorantagonisk
NO20084006L (no)	2008-09-26	Modulatorer av muskarinreseptorer
DK1729746T3 (da)	2010-03-08	Anordning til transdermal administration af nikotin
DK1418951T3 (da)	2010-05-10	Transdermalt teraeutisk system (TTS) med fentanyl som aktiv bestanddel
DK2059508T3 (da)	2012-07-23	5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister
EP2272524A3 (en)	2011-02-02	Y2 selective receptor agonists for therapeutic interventions
NO20082345L (no)	2008-05-23	Selektive VPAC2 reseptorpeptidagonister
MA28580B1 (fr)	2007-05-02	3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
ATE484506T1 (de)	2010-10-15	Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
EA200802104A1 (ru)	2009-04-28	Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
DE602005005298D1 (de)	2008-04-24	1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk
ATE460404T1 (de)	2010-03-15	Modulatoren von alpha7-nikotin-acetylcholin- rezeptoren und therapeutische anwendungen davon
EP1729857A4 (en)	2009-04-08	METHOD, APPARATUS AND MEANS FOR FIRE EXTINGUISHING
DK1420789T3 (da)	2007-09-17	Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
DK1809267T3 (da)	2009-05-18	Farmaceutiske kompositioner baseret på NK2-antagonister til pædiatrisk anvendelse
ATE541585T1 (de)	2012-02-15	Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
DE502005005571D1 (de)	2008-11-13	Steuergerät zur ansteuerung von personenschutzmitteln